artemisinin-based combination therapy

artemisinin-based combination therapy
Name	Artemisinin-based combination therapy
Routes	Oral, intravenous

artemisinin-based combination therapy is a class of antimalarial regimens that pair an artemisinin derivative with a partner drug to treat Plasmodium falciparum and other Plasmodium infections. Developed in response to rising drug resistance, these combinations became central to global malaria control strategies endorsed by organizations such as the World Health Organization, Global Fund to Fight AIDS, Tuberculosis and Malaria, Bill & Melinda Gates Foundation, and national programs like Centers for Disease Control and Prevention. Major regimen components include derivatives such as artemether, artesunate, and dihydroartemisinin combined with partner agents like lumefantrine, mefloquine, or piperaquine, and are widely deployed across regions including Sub-Saharan Africa, Southeast Asia, and South America.

Introduction

Artemisinin derivatives trace to the discovery of artemisinin by Tu Youyou from studies linked to the Chinese Academy of Traditional Chinese Medicine and projects like Project 523. Following clinical development influenced by institutions such as Oxford University and manufacturing scale-up by firms in India and China, artemisinin-based combinations were recommended in the 2000s by the World Health Organization as first-line therapy against falciparum malaria, replacing sulfadoxine–pyrimethamine and chloroquine in many national formularies including those of Nigeria, India, and Brazil.

Pharmacology and Mechanism of Action

Artemisinin derivatives (artesunate, artemether, dihydroartemisinin) share an endoperoxide bridge essential for activity, with biotransformation occurring in the liver via enzymes including cytochrome P450 isoforms studied at centers like National Institutes of Health. The proposed mechanism involves iron-mediated cleavage of the endoperoxide yielding free radicals that damage parasite proteins and membranes within infected erythrocytes; experimental elucidation has been advanced by laboratories at Harvard University, Pasteur Institute, and Johns Hopkins University. Partner drugs such as lumefantrine, amodiaquine, mefloquine, and piperaquine act via distinct targets and kinetics, providing synergistic parasite clearance and reduced probability of selecting for resistance, a principle informed by evolutionary models developed at Imperial College London and University of Oxford.

Clinical Use and Guidelines

Clinical guidance from the World Health Organization, European Medicines Agency, and national regulators specifies artemisinin-based combinations for uncomplicated Plasmodium falciparum malaria and severe malaria adjunctive use of intravenous artesunate as per protocols from World Health Organization and Centers for Disease Control and Prevention. Common regimens include artemether–lumefantrine, artesunate–amodiaquine, artesunate–mefloquine, dihydroartemisinin–piperaquine, and artesunate–sulfadoxine–pyrimethamine in intermittent preventive therapy, with dosing schedules informed by trials at institutions like London School of Hygiene & Tropical Medicine, University of Cape Town, and Mahidol University. Policy implementation has involved stakeholder coordination among Ministry of Health (Nigeria), National Malaria Control Programme (India), Pan American Health Organization, and procurement channels managed by the Global Fund.

Efficacy and Resistance

Artemisinin combinations produced rapid parasite clearance and reduced mortality demonstrated in landmark trials conducted by groups at Vietnam Military Medical Academy, University of Oxford, and University of California, San Francisco. However, delayed parasite clearance and resistance-associated mutations in the parasite kelch13 gene were first reported from the Greater Mekong Subregion, with surveillance by networks such as the Worldwide Antimalarial Resistance Network and research by Centers for Disease Control and Prevention and Wellcome Trust] ]affiliates. Resistance dynamics involve partner-drug failures, cross-border spread documented between Cambodia, Thailand, and Myanmar, and genomic studies from Wellcome Sanger Institute and Broad Institute informing containment strategies advocated by the World Health Organization.

Safety and Adverse Effects

Artemisinin-based regimens are generally well tolerated; common adverse effects include transient nausea, headache, and elevated liver enzymes described in trials at Karolinska Institutet and University of Nairobi. Specific partner drugs carry recognizable toxicities: mefloquine-associated neuropsychiatric events monitored by Food and Drug Administration and European Medicines Agency; amodiaquine-related agranulocytosis reported in pharmacovigilance from World Health Organization and Medicines and Healthcare products Regulatory Agency; piperaquine QT prolongation evaluated in studies at University of Melbourne and Monash University. Safety in pregnancy and children has been examined in cohorts overseen by UNICEF and the Malaria Clinical Trials Alliance.

Public Health Implementation and Access

Scaling artemisinin-based combinations required supply-chain coordination involving manufacturers across China, India, and Switzerland and distribution through channels supported by the Global Fund, United States Agency for International Development, and Clinton Health Access Initiative. Challenges include counterfeit and substandard antimalarials documented in investigations by Interpol, World Health Organization and regional regulatory authorities, and financing gaps addressed by partnerships with Gavi, the Vaccine Alliance and national ministries like Ministry of Health (Uganda). Community-level delivery strategies have drawn on programs by MSF (Doctors Without Borders), PATH, and Roll Back Malaria Partnership to integrate diagnostics via rapid diagnostic tests produced by firms certified by the Foundation for Innovative New Diagnostics.

Research and Future Directions

Ongoing research priorities include novel partner drugs, triple combination therapies evaluated by consortia at Bill & Melinda Gates Foundation-funded centers, next-generation endoperoxide compounds developed at Novartis Institute for Tropical Diseases and academic labs at University of Basel, and vaccine integration strategies aligned with the RTS,S program supported by GSK and PATH. Genomic surveillance initiatives by Wellcome Sanger Institute, Broad Institute, and Institut Pasteur aim to map resistance alleles and guide adaptive policies from agencies such as World Health Organization and National Institutes of Health, while operational research in transmission settings by LSHTM and Ifakara Health Institute informs elimination goals set by regional bodies like African Union and Association of Southeast Asian Nations.

Category:Antimalarial drugs